Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan

摘要: Purpose The combination of a vascular endothelial growth factor (VEGF) –neutralizing antibody, bevacizumab, and irinotecan is associated with high radiographic response rates improved survival outcomes in patients recurrent malignant gliomas. aim these retrospective studies was to evaluate tumor vascularity expression components the VEGF pathway hypoxic responses as predictive markers for benefit from bevacizumab therapy. Patients Methods In phase II trial, 60 astrocytomas were treated irinotecan. Tumor specimens collected at time diagnosis available further pathologic 45 (75%). VEGF, receptor-2, CD31, hypoxia-inducible carbonic anhydrase 9 (CA9), factor-2α semiquantitatively assessed by immunohistochemistry. Radiographic correlated angiogenic hy...